$0.51
3.85%
Nasdaq, Fri, Dec 27 2024
ISIN
US00534A1025
Symbol
ADGI

Adagio Therapeutics Inc Stock price

$0.51
-0.16 24.35% 1M
-0.69 57.50% 6M
-3.43 87.06% YTD
-3.54 87.41% 1Y
-8.49 94.33% 3Y
-16.49 97.00% 5Y
-16.49 97.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.02 3.85%
ISIN
US00534A1025
Symbol
ADGI
Sector
Industry

Key metrics

Market capitalization $61.00m
Enterprise Value $-44.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.23
EV/Sales (TTM) EV/Sales -3.83
P/S ratio (TTM) P/S ratio 5.28
P/B ratio (TTM) P/B ratio 0.73
Revenue (TTM) Revenue $11.56m
EBIT (operating result TTM) EBIT $-235.00m
Free Cash Flow (TTM) Free Cash Flow $-192.27m
Cash position $106.87m
EPS (TTM) EPS $-1.95
P/E forward negative
P/S forward 2.35
EV/Sales forward negative
Short interest 21.14%
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Adagio Therapeutics Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
12 12
-
100%
- Direct Costs 3.01 3.01
75% 75%
26%
8.56 8.56
598% 598%
74%
- Selling and Administrative Expenses 60 60
2% 2%
518%
- Research and Development Expense 182 182
60% 60%
1,571%
-233 -233
34% 34%
-2,015%
- Depreciation and Amortization 2.11 2.11
23% 23%
18%
EBIT (Operating Income) EBIT -235 -235
34% 34%
-2,033%
Net Profit -225 -225
33% 33%
-1,948%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 94
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today